Virtus ETF Advisers LLC Crinetics Pharmaceuticals, Inc. Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

A detailed history of Virtus ETF Advisers LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 1,962 shares of CRNX stock, worth $107,360. This represents 0.05% of its overall portfolio holdings.

Number of Shares

1,962

Previous 1,931 1.61%

Holding current value

$107,360

Previous $86,000 16.28%

% of portfolio

0.05%

Previous 0.04%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$43.83 - $54.98 $1,358 - $1,704	31 Added 1.61%	1,962 $100,000
Q2 2024 Aug 14, 2024	SELL	$42.12 - $51.91 $23,081 - $28,446	-548 Reduced 22.11%	1,931 $86,000
Q1 2024 May 15, 2024	SELL	$34.76 - $46.81 $6,083 - $8,191	-175 Reduced 6.59%	2,479 $116,000
Q4 2023 Feb 15, 2024	SELL	$25.62 - $37.07 $56,235 - $81,368	-2,195 Reduced 45.27%	2,654 $94,000
Q3 2023 Nov 07, 2023	SELL	$15.97 - $30.59 $7,729 - $14,805	-484 Reduced 9.08%	4,849 $144,000
Q2 2023 Aug 14, 2023	SELL	$15.73 - $23.6 $13,873 - $20,815	-882 Reduced 14.19%	5,333 $96,000
Q1 2023 May 15, 2023	SELL	$15.31 - $21.1 $36,483 - $50,281	-2,383 Reduced 27.72%	6,215 $99,000
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $36,711 - $45,148	2,370 Added 38.05%	8,598 $157,000
Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $869 - $1,073	48 Added 0.78%	6,228 $122,000
Q2 2022 Aug 12, 2022	SELL	$16.49 - $27.64 $2,737 - $4,588	-166 Reduced 2.62%	6,180 $115,000
Q1 2022 May 16, 2022	SELL	$17.15 - $28.31 $6,516 - $10,757	-380 Reduced 5.65%	6,346 $139,000
Q4 2021 Feb 14, 2022	SELL	$19.35 - $28.41 $87,055 - $127,816	-4,499 Reduced 40.08%	6,726 $191,000
Q3 2021 Nov 15, 2021	SELL	$16.88 - $25.23 $9,874 - $14,759	-585 Reduced 4.95%	11,225 $236,000
Q2 2021 Aug 10, 2021	SELL	$15.9 - $21.15 $160,144 - $213,022	-10,072 Reduced 46.03%	11,810 $223,000
Q1 2021 May 17, 2021	BUY	$13.3 - $17.55 $5,253 - $6,932	395 Added 1.84%	21,882 $334,000
Q4 2020 Feb 12, 2021	BUY	$12.08 - $17.46 $25,561 - $36,945	2,116 Added 10.92%	21,487 $303,000
Q3 2020 Nov 13, 2020	SELL	$13.62 - $17.66 $36,161 - $46,887	-2,655 Reduced 12.05%	19,371 $304,000
Q2 2020 Aug 05, 2020	BUY	$13.04 - $23.23 $287,219 - $511,663	22,026 New	22,026 $386,000
Q2 2019 Aug 13, 2019	SELL	$21.48 - $27.71 $170,422 - $219,851	-7,934 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$21.07 - $29.31 $23,177 - $32,241	-1,100 Reduced 12.18%	7,934 $181,000
Q4 2018 Feb 05, 2019	BUY	$22.4 - $35.39 $202,361 - $319,713	9,034 New	9,034 $271,000

Others Institutions Holding CRNX

# of Institutions

241

Shares Held

79.6M

Call Options Held

23.3K

Put Options Held

44.3K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.94B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Crinetics Pharmaceuticals, Inc. Transaction History